title: Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy.
abstract: BACKGROUND
  Data are limited regarding the risks and benefits of thrombolytic therapy for acute ischemic stroke outside of clinical trials.
  
  
  OBJECTIVE
  To investigate predictors of in-hospital mortality in patients with ischemic stroke treated with intravenous tissue plasminogen activator (tPA) within a pooled analysis of large German stroke registers.
  
  
  METHODS
  Prospective, observational cohort study conducted at 225 community and academic hospitals throughout Germany cooperating within the German Stroke Registers Study Group.
  
  
  METHODS
  A total of 1658 patients with acute ischemic stroke who were admitted to study hospitals between 2000 and 2002 and were treated with tPA.
  
  
  METHODS
  In-hospital mortality.
  
  
  RESULTS
  One hundred sixty-six patients (10%) who received tPA died during hospitalization, with 67.5% of these deaths occurring within 7 days. Factors predicting in-hospital death after tPA use were older age (for each 10-year increment in age, adjusted odds ratio [OR], 1.6; 95% confidence interval [CI], 1.3-1.9) and altered level of consciousness (adjusted OR, 3.4; 95% CI, 2.4-4.7). The overall rate of symptomatic intracranial hemorrhage was 7.1% and increased with age. One or more serious complications was observed in 27.2% of all patients and in 83.9% of patients who died after tPA treatment. An inverse relation between the number of patients treated with tPA in the respective hospital and the risk of in-hospital death was observed (adjusted OR, 0.97; 95% CI, 0.96-0.99 for each additional patient treated with tPA per year).
  
  
  CONCLUSIONS
  In patients with ischemic stroke who are treated with tPA, disturbances of consciousness and increasing age are associated with increased in-hospital mortality.
authors.affiliation: Institute of Epidemiology and Social Medicine, University of Muenster, and Department of Quality Assurance, Westphalian Board of Physicians, Muenster, Germany;
authors.forename: Peter U
authors.initials: PU
authors.lastname: Heuschmann
authors.forename: Peter L
authors.initials: PL
authors.lastname: Kolominsky-Rabas
authors.forename: Joachim
authors.initials: J
authors.lastname: Roether
authors.forename: Bjoern
authors.initials: B
authors.lastname: Misselwitz
authors.forename: Klaus
authors.initials: K
authors.lastname: Lowitzsch
authors.forename: Jan
authors.initials: J
authors.lastname: Heidrich
authors.forename: Peter
authors.initials: P
authors.lastname: Hermanek
authors.forename: Carsten
authors.initials: C
authors.lastname: Leffmann
authors.forename: Matthias
authors.initials: M
authors.lastname: Sitzer
authors.forename: Marcel
authors.initials: M
authors.lastname: Biegler
authors.forename: Hans-Joachim
authors.initials: HJ
authors.lastname: Buecker-Nott
authors.forename: Klaus
authors.initials: K
authors.lastname: Berger
mesh_terms: D000368:Aged; D002545:Brain Ischemia; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012306:Risk; D020521:Stroke / Q000188:drug therapy* / Q000401:mortality*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator